Brain cancer clue hunt: new biomarkers may predict drug success
NCT ID NCT03144167
First seen Jan 20, 2026 · Last updated Apr 30, 2026 · Updated 17 times
Summary
This study is looking for biological markers that can predict if a glioblastoma patient will survive at least 6 months after treatment with the drug bevacizumab. Researchers will use special brain scans to measure certain chemicals in the tumor. The goal is to identify which patients are most likely to benefit from this expensive treatment and avoid giving it to those who won't respond. About 170 adults with recurrent glioblastoma will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Amiens Picardie
RECRUITINGAmiens, Picardie, 80054, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.